October 19, 2001 — TORONTO — Pharmaceutical company Aventis Pasteur has begun construction on a $19 million state-of-the-art facility that will be used to develop therapeutic vaccines for cancer.
Company officials say the facility, complete with approximately 10,000 square feet of cleanroom space, will also include Canada’s first robotic arm for use in vaccine production. The arm will also minimize human handling of the sensitive cell and viral cultures.
“The new facility?is the result of recognizing that therapeutic cancer vaccines require a serious research and development commitment,” said J. Mark Lievonen, president of Aventis Pasteur Limited. “Researchers and technicians located in this new facility will focus on the development and clinical manufacture of therapeutic vaccines for cancer.”
The facility is slated to be open by November. 2002.